Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

Table 1 Status of 186 cases of pseudomyxoma of abdominal cavity treated by cell reduction combined with intraperitoneal hyperthermic chemotherapy, n (%)

Variable	Number of cases
Primary site
Appendix	170 (91.4)
Ovary	15 (8.1)
Location	1 (0.5)
Pathological type
Low-level	99 (53.2)
High level	57 (30.6)
Not quite clear	30 (16.1)
Lymph node metastasis
Correct	19 (10.2)
Deny	151 (81.2)
Suspicious transfer	16 (8.6)
Meningeal tumor index score
≤ 10	7 (3.8)
11-20	34 (18.3)
21-30	56 (30.1)
31-39	55 (29.6)
Not quite clear	34 (18.3)
CCR rating
CCR-0	15 (8.1)
CCR-1	40 (21.5)
CCR-2/3	113 (60.8)
Not quite clear	18 (9.7)
Whether to combine organ resection
Correct	123 (66.1)
Deny	63 (33.9)
HIPEC count
1	30 (16.1)
2	48 (25.8)
3	79 (42.5)
4	25 (13.4)
5	4 (2.2)
HIPEC drugs
Raltitrexed	47 (25.3)
Letotrexate + Oxaliplatin + Mitomycin	42 (22.6)
Platinum	32 (17.2)
Letotrexate + Oxaliplatin	25 (13.4)
Letotrexate + Mitomycin	20 (10.8)
Mitomycin	8 (4.3)
Oxaliplatin + Mitomycin	8 (4.3)
Other	4 (2.2)

HIPEC: Intraperitoneal hyperthermic chemotherapy; CCR: Cell reduction degree.

Table 2 186 patients with pseudomyxoma were treated with cell reduction combined with intraperitoneal hyperthermic chemotherapy

Incidence of complications	n (%)
Death 30 days after surgery	5 (2.7)
Death 90 days after surgery	8 (4.3)
Further surgery is required	3 (1.6)
Grade III-IN complications	80 (43.0)
Gastrointestinal anastomotic leakage	4 (2.2)
Urinary system complications (ureteral injury, urinary leakage, etc.)	1 (0.5)
Abdominal bleeding	4 (2.2)
Abdominal infection	8 (4.3)
Wound infection	2 (1.1)
Sepsis or sepsis	1 (0.5)
Urinary tract infection	1 (0.5)
Ascites	4 (2.2)
Pneumonia	10 (5.4
Pneumothorax	2 (1.1)
Cardiac insufficiency or heart failure	2 (1.1)
Renal insufficiency	1 (0.5)
Hepatic insufficiency	19 (10.2)
Septic shock	2 (1.1)
Hemorrhagic shock	2 (1.1)
Albumin reduction	14 (7.5)
Hemoglobin reduction	51 (27.4)
Thrombocytopenia	2 (1.1)
Electrolyte disturbance	21 (11.6)
Coagulopathy	11 (5.9)

Table 3 Analysis of factors of incidence of grade III to IV complications in pseudomyxoma of abdominal cavity undergoing cell reduction combined with intraperitoneal

Clinical variables	Cases	Grade III-IV complications incidence rate, n (%)	χ2	P value
Age (years)			0.105	0.746
Up to 60	121	51 (42.1)
Greater than 60	65	29 (44.6)
Gender			0.088	0.766
Male	65	27 (41.5)
Female	121	53 (43.8)
Primary site			2.552	0.225
Appendix	170	71 (41.8)
Ovary	15	9 (9/15)
Other	1	0
Pathological level			0.278	0.598
Low-level	99	46 (46.5)
High level	57	24 (42.1)
Lymph node metastasis			0.349	0.818
Correct	19	8 (8/19)
Deny	151	64 (42.4)
Suspicious transfer	16	8 (8/16)
Peritoneal tumor index score (points)			1.332	0.536
≤ 20	41	16 (39.0)
21-39	111	55 (49.5)
Whether to combine organ resection			14.33	< 0.001
Correct	123	65 (52.8)
Deny	63	15 (23.8)
HIPEC count			4.9	0.298
1	30	17 (56.7)
2	48	16 (33.3)
3	79	34 (43.0)
4	25	12 (48.0)
5	4	1 (1/4)

HIPEC: Intraperitoneal hyperthermic chemotherapy.

Table 4 Efficacy of cytopenia combined with Intraperitoneal hyperthermic chemotherapy to observe the survival of patients with peritoneal pseudomyxoma with different clinical features

Variable	Cases	5-year OS (%)	95%CI (%)	P value
Age (years)				0.480
Up to 60	121	48.7	36.9-60.5
Greater than 60	65	54.2	37.9-70.5
Gender				0.139
Male	65	41.8	26.1-57.5
Female	121	55.4	43.6-67.2
Primary site				0.701
Appendix	170	50.6	40.6-60.6
Ovary	15	49.5	16.8-82.2
Other	l
Pathological level				< 0.00
Low-level	99	68.1	54.8-81.4
High level	57	26.3	11.0-41.6
Lymph node metastasis				0.107
Correct	19	54.3	27.8-80.8
Deny	151	49.4	39.2-59.6
Suspicious transfer	16	66.7	13.4-100.0
Peritoneal tumor index score (points)			0.001	0.001
≤ 20	41	82.1	67.4-96.8
21-39	111	44.0	30.5-57.5
CCR score				< 0.001
CCR-0	15	88.9	68.3-100.0
CCR-1	40	77.6	62.7-92.5
CCR-2/3	113	42.0	29.5-54.5
Whether to combine organ resection				0.915
Correct	123	46.3	32.8-59.8
Deny	63	54.7	40.8-68.6
HIPEC treatment plan				0.597
Raltitrexed	47	67.7	51.4~84.0
Oxaliplatin + Letotrexate + Mitomycin	42	50.8	23.8~77.8
Platinum	32	40.2	21.4-59.0
Oxaliplatin + Letotrexate	25	30.0	9.0-51.0
Letotrexate + Mitomycin	20	100
Mitomycin	8	50.0	10.0-90.0
Oxaliplatin + Mitomycin	8	37.5	4.0-71.0
Other	4	50.0	1.0-99.0

HIPEC: Intraperitoneal hyperthermic chemotherapy; CCR: Cell reduction degree; OS: Overall survival.